Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 16, 2021

Emergex obtains approval to commence Phase I trial of Covid-19 vaccine 

Subject dosing in the trial to assess safety and tolerability of the vaccine will begin in January next year.

Emergex Vaccines has obtained regulatory approvals to commence the Phase I clinical trial of its Covid-19 vaccine candidate.

The double-blind, randomised, comparator-controlled trial will analyse the safety and tolerability of high and low doses of the vaccine.

To be conducted by the University of Lausanne, Switzerland Center for Primary Care and Public Health professor Blaise Genton, the trial will enrol a total of 13 subjects into two groups.

The company expects to dose the first subject with the first dose of the vaccine in January 2022.

Apart from safety and tolerability, the trial will offer information on CD8+ T-Cell-facilitated immune responses as a measure of protection against SARS-CoV-2 infection.

Emergex Vaccines chief commercial officer Robin Cohen said: “Our T Cell priming vaccines may offer significant benefits over current Covid-19 vaccines, including longer-lasting immunity and broader protection against new variants.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

“We are proud to announce the initiation of this trial and look forward to gathering data to support the development of this important next-generation vaccine.”

The company is currently carrying out another Phase I trial of its dengue vaccine candidate in Switzerland.

All the subjects in this naNO-DENGUE trial have received two doses of the shot.

The vaccines developed by Emergex are designed to prime naive CD8+ T-Cells to produce virus-specific CD8+ T-cells/Cytotoxic T Lymphocytes (CTLs) to destroy cells infected by the virus.

This approach also averts disease, hinders replication of the virus and lowers symptoms and disease transmission.

The company claimed that as against currently available vaccine technologies that depend on an antibody immune response, its T-Cell priming vaccines can potentially be more efficient in targeting viruses that mutate, thereby avoiding the booster shot requirements.

Emergex also stated that its vaccine may offer cross-reactive immunity to the SARS-CoV-1 virus, as well as all variants and strains of SARS-CoV-2, thereby providing wide-ranging immune protection from two viruses with a single vaccine.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU